Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA

Journey Medical Corporation's (DERM) shares rose 10% on Mar 18, after the company announced that its new drug application (NDA) for its key pipeline candidate, DFD-29 capsules (40mg), to treat inflammatory lesions and erythema of rosacea in adults, has been accepted by the FDA for review.A decision from the regulatory body is expected on Nov 4, 2024.The NDA submission was based on positive data from Journey Medical’s two phase III studies (MVOR-1 and MVOR-2) of DFD-29 for treating rosacea. Both studies achi ...